- Home
- JXG vs SYRS Comparison
JXG vs SYRS Comparison
Compare JXG & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXG
- SYRS
- Stock Information
- Founded
- JXG N/A
- SYRS 2011
- Country
- JXG China
- SYRS United States
- Employees
- JXG N/A
- SYRS N/A
- Industry
- JXG
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- JXG
- SYRS Health Care
- Exchange
- JXG Nasdaq
- SYRS Nasdaq
- Market Cap
- JXG 5.2M
- SYRS 5.7M
- IPO Year
- JXG N/A
- SYRS 2016
- Fundamental
- Price
- JXG $2.39
- SYRS $0.17
- Analyst Decision
- JXG
- SYRS Hold
- Analyst Count
- JXG 0
- SYRS 5
- Target Price
- JXG N/A
- SYRS $3.00
- AVG Volume (30 Days)
- JXG 34.7K
- SYRS 1.2M
- Earning Date
- JXG 12-06-2024
- SYRS 03-26-2025
- Dividend Yield
- JXG N/A
- SYRS N/A
- EPS Growth
- JXG N/A
- SYRS N/A
- EPS
- JXG 2.20
- SYRS N/A
- Revenue
- JXG $38,490,872.00
- SYRS $386,000.00
- Revenue This Year
- JXG N/A
- SYRS N/A
- Revenue Next Year
- JXG N/A
- SYRS N/A
- P/E Ratio
- JXG $1.09
- SYRS N/A
- Revenue Growth
- JXG N/A
- SYRS N/A
- 52 Week Low
- JXG $0.75
- SYRS $0.16
- 52 Week High
- JXG $4.92
- SYRS $7.96
- Technical
- Relative Strength Index (RSI)
- JXG N/A
- SYRS 38.78
- Support Level
- JXG N/A
- SYRS $0.16
- Resistance Level
- JXG N/A
- SYRS $0.20
- Average True Range (ATR)
- JXG 0.00
- SYRS 0.02
- MACD
- JXG 0.00
- SYRS 0.01
- Stochastic Oscillator
- JXG 0.00
- SYRS 35.75
About JXG JX Luxventure Limited Common Stock
JX Luxventure Group Inc, formerly JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.